The targeted drug delivery devices market for biologics is projected to be worth around USD 5 billion in 2030, claims Roots Analysis

Driven by the urgent need to address off-target toxicity-related concerns and improve therapeutic outcomes of biologic drugs, several patient-centric medical devices that facilitate drug delivery to desired physiological regions, are being developed

Roots Analysis has announced the addition of “Targeted Drug Delivery System Market” report to its list of offerings. 

Despite the many benefits offered by biologics, they are associated with a number of challenges, such as delivery-related complexities, immunogenicity concerns, compromised efficacy and need for periodic administration (cell therapies). To address some of these concerns, several innovator companies are actively engaged in identifying targeted and effective delivery strategies for biologics, including gene therapies, cell / stem cell therapies, immunotherapies and therapeutic proteins.

To order this 280+ page report, which features 90+ figures and 135+ tables, please visit this https://www.rootsanalysis.com/reports/targeted-drug-delivery.html

Key Market Insights 

Around 30 devices have been / are being developed for the targeted delivery of biologics

Majority (30%) of such devices involve the encapsulation of the active drug substance, followed by catheter-based devices (19%) and implants (19%). It is worth highlighting that, around 50% of the products mentioned in the report are currently being evaluated in the preclinical stages, while 37% are in clinical trials. 

The developer landscape is dominated by the presence of small companies, having less than 50 employees 

The small players, developing targeted biologic delivery devices, represent around 70% of the competitive landscape. Although the majority (53%) of stakeholders are industry players, there are several non-industry players engaged in this domain. 

Over 350 clinical trials of drugs / therapies that are likely to require intra-organ / targeted delivery, have been registered till 2020

Of the abovementioned clinical research studies, more than 180 were focused on stem cell therapies, while the rest were related to various gene therapies. It is worth noting that 21,300+ patients have been enrolled, so far, in these trials, with the highest enrolment in studies evaluating treatments for oncological disorders.

The targeted drug delivery devices market for biologics is projected to grow at CAGR of 89%, till 2030 

Presently, the majority (70%) revenue share is expected to come in from the sales of catheters, followed by the contribution of encapsulation-based delivery devices (USD 8.9 million). However, the analytical insights in the report indicate that the share of cannulas is likely to grow at a relatively faster pace (102%), between 2023 and 2030. 

To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/targeted-drug-delivery/request-sample.html

Key Questions Answered

• What are the various type of devices that facilitate the targeted delivery of biologics?
• Who are the leading players involved in the development of targeted delivery devices for biologics?
• What are the key therapeutic areas for which targeted biologic delivery devices are presently being developed?
• Which companies are likely to enter into strategic partnerships with for device developers engaged in this domain?
• How is the current and future opportunity likely to be distributed across key market segments?

The USD 4.9 billion (by 2030) financial opportunity within the targeted drug delivery market for biologics has been analyzed across the following segments:

• Type of Device
  • Encapsulation based Delivery Device 
  • Catheters
  • Electroporation Delivery Systems
  • Cannulas 
• Target Organ
  • Heart
  • Brain
  • Eye
  • Skin
  • Breast
  • Pancreas
• Target Therapeutic Area
  • Oncological Disorders
  • Cardiovascular Disorders
  • Neurological Disorders
  • Metabolic Disorders
  • Ophthalmic Diseases
• Target Indication
  • Melanoma
  • Breast Cancer
  • Heart Failure
  • Myocardial Ischemia
  • Parkinson's Disease
  • Glioblastoma
  • Non-infectious Uveitis
  • Macular Telangectasia Type 2
  • Glaucoma
  • Retinitis Pigmentosa
  • Pancreatic Cancer
  • Mucopolysaccharidosis Type III A
• Key Geographical Regions 
  • North America
  • Europe
  • Asia Pacific 

The report features inputs from eminent industry stakeholders, according to whom, owing to their potential to enhance the efficacy of delivered biologics, the market for targeted delivery devices is expected to witness steady growth over the the next decade. The report includes detailed transcripts of discussions held with the following experts:

• William L Rust (Founder and Chief Executive Officer, Seraxis)
• Manuel Pires (Junior Business Developer, Defymed)
• R. Lyle Hood (Assistant Professor, University of Texas at San Antonio)
• Anonymous (Postdoctoral Associate, Massachusetts Institute of Technology)

The research includes detailed profiles of devices (listed below), featuring an overview of the device, its mechanism of action, key development-related highlights and key clinical trial results.

• Alcyone MEMS Cannula (AMCTM) (Alcyone Lifesciences)
• Bullfrog® Micro-Infusion Device (Mercator MedSystems)
• HelixTM Biotherapeutic Delivery System (BioCardia)
• Orbit Subretinal Delivery System (Gyroscope Therapeutics)
• SmartFlow® Neuro Ventricular Cannula (ClearPoint Neuro)
• Renexus® (Neurotech Pharmaceuticals)

For additional details, please visit https://www.rootsanalysis.com/reports/targeted-drug-delivery.html or email sales@rootsanalysis.com

Contact:

Gaurav Chaudhary
Gaurav.Chaudhary@rootsanalysis.com